STRS Ohio’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

STRS Ohio’s Portfolio BLPH Stock Details BLPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-900	Closed	-$4K	–	2536
2021 Q1	$4K	Hold	900	–	–	﹤0.01%	2158
2020 Q4	$6K	Hold	900	–	–	﹤0.01%	2129
2020 Q3	$9K	Hold	900	–	–	﹤0.01%	2137
2020 Q2	$11K	Buy	+900	New	+$12.6K	﹤0.01%	2094

Other funds holding BLPH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $127M AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

STRS Ohio's BLPH Position: Q2 2021 in Review

STRS Ohio sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q2 2021, closing a stake of 900 shares — an estimated $4K sold.

STRS Ohio first reported a position in BLPH in Q2 2020 and held it in 4 quarters. The position peaked at $11K in Q2 2020. 27 funds tracked by Wall St. Rank hold BLPH as of Q2 2021.

STRS Ohio reported no remaining Bellerophon Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
STRS Ohio sold 900 Bellerophon Therapeutics, Inc. shares in Q2 2021, an estimated $4K.
STRS Ohio first reported a position in Bellerophon Therapeutics, Inc. in Q2 2020 and held it in 4 quarters.
STRS Ohio's Bellerophon Therapeutics, Inc. position peaked at $11K in Q2 2020.
27 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q2 2021.

Based on STRS Ohio's 13F filing for Q2 2021, filed 26 Jul 2021.